{
    "clinical_study": {
        "@rank": "149736", 
        "arm_group": [
            {
                "arm_group_label": "EVARREST\u2122 Fibrin Sealant Patch", 
                "arm_group_type": "Experimental", 
                "description": "EVARREST\u2122 Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts \u2014 a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin)."
            }, 
            {
                "arm_group_label": "Standard of Care (SoC)", 
                "arm_group_type": "Other", 
                "description": "SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.   For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL)."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and hemostatic effectiveness of EVARREST\u2122 Fibrin Sealant Patch\n      (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding\n      during hepatic surgery."
        }, 
        "brief_title": "The EVARREST\u2122 Fibrin Sealant Patch Liver Study", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemorrhage", 
        "condition_browse": {
            "mesh_term": "Hemorrhage"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects \u2265 18 years of age, requiring elective or urgent, open hepatic surgery.\n\n          -  Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as\n             identified intra-operatively by the surgeon\n\n          -  Subjects or legally authorized representatives must be willing to participate in the\n             study, and provide written informed consent. (Note: This criteria does allow for\n             hospital translators to be used where approved by Ethics Committees/Institutional\n             Review Boards)\n\n        Exclusion Criteria:\n\n          -  Subjects with any intra-operative findings identified by the surgeon that may\n             preclude conduct of the study procedure;\n\n          -  TBS is from large defects in arteries or veins where the injured vascular wall\n             requires repair with maintenance of vessel patency and which would result in\n             persistent exposure of EVARREST\u2122 to blood flow and pressure during healing and\n             absorption of the product;\n\n          -  TBS with major arterial bleeding requiring suture or mechanical ligation;\n\n          -  Subjects admitted for trauma surgery;\n\n          -  Subject is a transplant patient for fulminant hepatic failure\n\n          -  Subject with TBS within an actively infected field;\n\n          -  Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony\n             confine;\n\n          -  Subjects with known intolerance to blood products or to one of the components of the\n             study product or is unwilling to receive blood products;\n\n          -  Subjects who are known, current alcohol and / or drug abusers;\n\n          -  Subjects who have participated in another investigational medical device or\n             investigational drug trial within 30 days of surgery or are expected to participate\n             in another medical device or investigational drug trial during the course of the\n             study;\n\n          -  Female subjects who are pregnant or nursing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993888", 
            "org_study_id": "BIOS-13-005", 
            "secondary_id": "2013-002535-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "EVARREST\u2122 Fibrin Sealant Patch", 
                "intervention_name": "EVARREST\u2122 Fibrin Sealant Patch", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Standard of Care (SoC)", 
                "intervention_name": "Standard of Care (SoC)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Hepatobiliary Surgery", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Clinical Investigation Site #13"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "Clinical Investigation Site #10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "Clinical Investigation Site #12"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Clinical Investigation Site #16"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70121"
                    }, 
                    "name": "Clinical Investigation Site #15"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Clinical Investigation Site #9"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Clinical Investigation Site #11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Clinical Investigation Site #14"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Clinical Investigation Site #8"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Clinical Investigation Site #17"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "zip": "3004"
                    }, 
                    "name": "Clinical Investigation Site #3"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodville South", 
                        "country": "Australia", 
                        "zip": "5011"
                    }, 
                    "name": "Clinical Investigation Site #2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand", 
                        "zip": "93-503"
                    }, 
                    "name": "Clinical Investigation Site #1"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B15 2TH"
                    }, 
                    "name": "Clinical Investigation Site #6"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB2 0QQ"
                    }, 
                    "name": "Clinical Investigation Site #7"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "zip": "EH16 4SA"
                    }, 
                    "name": "Clinical Investigation Site #4"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "Clinical Investigation Site #5"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "New Zealand", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST\u2122 Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery", 
        "overall_contact": {
            "email": "jbatill2@its.jnj.com", 
            "last_name": "Jonathan Batiller, MBA", 
            "phone": "908-218-2492"
        }, 
        "overall_official": {
            "affiliation": "Ethicon, Inc.", 
            "last_name": "Richard Kocharian, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "New Zealand: Medsafe"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of subjects achieving hemostasis at the TBS at 4-minutes following randomization and with no re-bleeding requiring treatment at the TBS any time prior to initiation of wound closure. Hemostasis is defined as no detectable bleeding at the TBS.", 
            "measure": "Hemostasis at the Target Bleeding Site (TBS) at 4-minutes following randomization", 
            "safety_issue": "Yes", 
            "time_frame": "Intraoperative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993888"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Proportion of subjects achieving hemostatic success at 10 minutes following randomization", 
                "measure": "Hemostasis at the Target Bleeding Site (TBS) at 10-minutes following randomization", 
                "safety_issue": "Yes", 
                "time_frame": "Intraoperative"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 60-days"
            }, 
            {
                "measure": "Absolute time to hemostasis", 
                "safety_issue": "No", 
                "time_frame": "Intraoperative"
            }
        ], 
        "source": "Ethicon, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ethicon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}